7th annual Sales Force Effectiveness Europe Conference for Pharma
Do you have all the knowledge and contacts you need to increase sales and meet targets in the ever-changing and turbulent healthcare environment? Built on 7 years of success, the Sales Force Effectiveness Conference Europe is the only event that sales and marketing strategy innovators and leaders in sales and marketing need attend in order to find out the latest trends, network with like-minded peers and discuss common challenges. In healthcare environment where payors and government are under increasing pressure to cut costs and reduce spending and with a global recession looming, the pharmaceutical industry is under increasing pressure to deliver more value to it's customers, with less resources AND provide shareholder value. An impossible conundrum you may think.
With the changing healthcare environment, it has never been more essential for organisations to have accurate and first-rate forecasts, to enable strategic business decision-making and stay ahead of the competition.This two day intensive Summit will address the most important aspects of Forecasting and Marketing in Europe. Following on from years of highly successful Global Pharmaceutical Sales conferences eyeforpharma's latest offering in this field guarantees to take forecasting excellence to the next level.
7th annual Sales Force Effectiveness Europe Conference for Pharma
Do you have all the knowledge and contacts you need to increase sales and meet targets in the ever-changing and turbulent healthcare environment? Built on 7 years of success, the Sales Force Effectiveness Conference Europe is the only event that sales and marketing strategy innovators and leaders in sales and marketing need attend in order to find out the latest trends, network with like-minded peers and discuss common challenges. In healthcare environment where payors and government are under increasing pressure to cut costs and reduce spending and with a global recession looming, the pharmaceutical industry is under increasing pressure to deliver more value to it's customers, with less resources AND provide shareholder value. An impossible conundrum you may think.
Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15bn to $40bn during 2000–2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues.
Innovations in The Management of Diabetes: Next generation treatments and market dynamics
Diabetes has become the fifth leading cause of death across developed markets, and cases of the disease are forecast to grow by 7.1% across the globe by 2013. The market for innovative diabetes treatments will be driven by this projected rise in prevalence, together with the substantial unmet need for drugs that can effectively halt or reverse disease progression.
Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment
‘Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment’ explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area.
Valuing Pharmaceutical Innovation: Pricing and reimbursement for innovative therapies
Pricing and reimbursement strategies for innovative new drugs require significant evidence of beneficial clinical and economic outcomes using cost effectiveness and budget impact models.
The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses
The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% during 2004–2007. Regular patent expirations of blockbuster drugs are the primary growth driver of the industry. Rising healthcare expenditure has also contributed to industry expansion, with governments coming under growing pressure to provide low cost alternatives to branded drugs.
The Anti-Infectives Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
The Global Anti-infectives Market Outlook to 2013 provides comprehensive coverage of the anti-infectives market, incorporating the disease overview and detailed epidemiological analysis of the major indications.
Innovations and Pipelines for Respiratory Disorders: Niche markets, new products and future developments
‘Innovations and Pipelines for Respiratory Disorders’ is a report published by Business Insights that examines the future of the respiratory disorders market and explores the dynamics and drivers for current and emerging treatments.
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2013 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Neuropathic Pain - UCB's Vimpat set to compete with major players
The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017. The growth in the market is spurred on by the uptake of Pfizer's Lyrica (pregabalin), forecast to reach almost $3 billion in sales by 2017. Vimpat is the most promising pipeline drug, forecast to take some $480m by 2017.
Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highly efficacious. However, concerns surrounding the safety of HRT have led to an increase in demand for non-hormonal alternatives.
The Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you to compare the 50 players by current and forecast sales to 2012.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
With the growing cost of developing novel drugs, combined with the fact that fewer such drugs are gaining regulatory approval, the use of lifecycle management is playing an ever-more important role in the increasingly cost-conscious pharma industry. Rx-to-OTC switching is one such strategy employed to either enhance existing franchise revenues or protect branded revenues from generic competition.
Asthma - Over-prescribing is common in intermittent and mild forms of asthma
Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow limitation and controller medications to target underlying inflammation. Datamonitor's research shows that almost all patients (even those with mild intermittent asthma) receive some type of controller medication as their baseline treatment, which is in line with international management guidelines.
This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
In collaboration with Regulanet network of regulatory affairs consultants throughout Europe and USA, we keep
daily contacts and communication with National Agencies for Medicines
and Medical Devices. Beside regulatory we also maintain understanding of the business, scientific and technical background of products.
FarmavitaR+ Journal 
